Back

Relation of apolipoprotein C3 to risk of major adverse cardiovascular events and death after acute coronary syndrome on a background of optimized statin treatment

30 August 2024 (08:00 - 17:30)
Organised by: Logo
Congress Presentation Part of: Acute coronary syndromes: diagnosis, outcomes, and predictors Biomarkers ESC Professional Premium Access ESC Congress 2024 European Society of Cardiology

About the speaker

Photo
Professor Gregory Schwartz

University of Colorado School of Medicine, Aurora (United States of America)

6 More presentations in this session

Presentation thumbnail
Comparative analysis of vitamin K antagonists and direct oral anticoagulants for left ventricular thrombus management: a retrospective study utilising TriNetX
Doctor Z. Yao (Manchester, GB)
Abstract Slides Video
Presentation thumbnail
Early improvement in left ventricular microvascular flow post sonothrombolysis is associated with better left ventricular systolic function in st elevation myocardial infarction patients
Doctor L. Azevedo (Sao Paulo, BR)
Abstract Slides Video
Presentation thumbnail
Growth differentiation factor-15 and 5-years cardiovascular risk in chest pain patients presenting to the emergency department: a multicenter cohort study
Doctor L. Crisanti (Basel, CH)
Abstract Slides Video
Presentation thumbnail
Impact of neutrophil-to-lymphocyte ratio on clinical outcomes in patients with acute or chronic coronary syndrome undergoing percutaneous coronary intervention
Doctor A. Oliva (New York, US)
Abstract Slides Video
Presentation thumbnail
N-terminal prohormone of brain natriuretic peptide predicts recurrent cardiovascular events in patients with acute coronary syndrome both in the acute and post-discharge setting: a TRACER substudy
Associate Professor G. Batra (Uppsala, SE)
Abstract Slides Video

Access the full session

Session thumbnail
Acute coronary syndromes: diagnosis, outcomes, and predictors

The Event

Event poster

ESC Congress 2024

30 August - 2 September 2024
You may be interested in
thumbnail
Congress Presentation
Beyond LDL-cholesterol: effects of alirocumab on the human apolipoproteome
thumbnail
Congress Presentation
Inhibition of liver ApoC3 by GalNAc-conjugated siRNA RBD5044: first-in-human trial to evaluate the safety, pharmacokinetics (PK), and pharmacodynamic (PD) effects on atherogenic lipid profiles in heal
thumbnail
Congress Presentation
Efficacy and safety of Alirocumab once-monthly dosing in patients with atherosclerotic cardiovascular disease and without acute coronary syndrome or stroke; an ODYSSEY CHOICE I analysis

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources